Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 6Breast 5Gynecologic 3Gastrointestinal 3Sarcoma 2Tumor-Agnostic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Ovarian Neoplasms 2Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 74pembrolizumab 59Carboplatin 55Bevacizumab 54Specimen Handling 47Magnetic Resonance Spectroscopy 38Cisplatin 32olaparib 28Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 18Topotecan 17Nivolumab 17Doxorubicin 15Cyclophosphamide 15Immunoglobulin G 14Disulfides 14niraparib 12fludarabine 12lenvatinib 11Surveys and Questionnaires 11Letrozole 11atezolizumab 10Drug Therapy 10durvalumab 9Fulvestrant 9Docetaxel 9Brachytherapy 9mirvetuximab soravtansine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
talazoparib × Gynecologic × 90 days × Clear all
NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

Phase 2 Recruiting
36 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Pfizer

Phase 3 Active not recruiting
68 enrolled
Gynecologic

Ovarian Neoplasms

NCT04486352 2026-04-01

EndoMAP

Alliance Foundation Trials, LLC.

Phase 1/2 Recruiting
148 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡